Roche disclosed pricing and performance details for its Axelios 1 sequencing‑by‑expansion system, claiming a $150 list cost to sequence a 30× human genome and positioning the platform for launch this summer. Roche emphasized versatility across cancer genomics, methylation, and multi‑omics and said it will provide real‑world performance data as the product ships. Separately, Ultima Genomics launched its UG200 series and Solaris 2.0 workflows, touting higher throughput, faster turnaround, and lower instrument pricing to enable population‑scale sequencing. Ultima’s UG200 Ultra claims capacity to sequence over 60,000 human genomes per year at 30× on a dual‑wafer configuration. Market implication: New instrument entrants and aggressive per‑genome pricing intensify competition in high‑throughput sequencing, with downstream effects on population genomics projects, clinical sequencing economics, and adoption of multiomic applications.